SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

SpaceXs agreement to acquire low-band spectrum for Starlink Mobile sparked a sharp selloff in T-Mobile and other wireless carriers as traders weighed the prospect of a new competitor. The community is divided between seeing a meaningful long-term threat and calling the reaction excessive because building a competitive network would take substantial time and investment.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

SpaceXs agreement to acquire low-band spectrum for Starlink Mobile has intensified concerns about future competition, weighing on AT&T and other major wireless carriers. Traders are split between viewing the sharp selloff as an overreaction given the time and infrastructure needed to build a rival network and seeing a credible long-term threat; some are buying the dip for AT&Ts dividend.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax rallied alongside vaccine peers after reports of an NIH push to accelerate personalized cancer vaccines, with traders noting the move was largely sector-wide sympathy buying rather than a company-specific oncology announcement. The community also debated whether heavy short interest could amplify the move, while some pointed to Sanofis combination-vaccine trial as a separate potential catalyst.

Chevron Corporation. The Group's principal activities are providing administrative, financial and management support for fully integrated petroleum, chemicals and coal mining operations. Exploration and production operations consist of exploring, developing and producing crude oil and natural gas and marketing natural gas. Refining, marketing and transportation operations relate to refining crude oil into finished petroleum products, marketing crude oil, natural gas and transporting crude oil, natural gas and petroleum products. Chemical operations include manufacture and marketing of commodity petrochemicals, plastics for industrial uses and fuel and lubricant oil additives. The Other operations consist of coal mining operations, power generation business, worldwide cash management and debt financing activities, corporate administrative functions, insurance operations, real estate activities and technology companies.

Chevron Corp.

Middle East conflict and Strait of Hormuz supply risks are driving discussion of higher, volatile oil prices and Chevrons sensitivity to crude; traders debate whether the oil rally will translate into further gains for CVX or whether easing tensions and pullbacks in crude will weigh on shares. Chevrons planned Venezuela expansion is also discussed as a longer-term growth opportunity, with execution and political risks noted.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

AXSM is drawing attention amid a steep, sustained share-price decline that investors say lacks a clear explanation, with frustration focused on managements limited communication. The debate centers on whether Auvelitys Alzheimers agitation launch is gaining traction: bulls cite rising prescriptions and possible data undercounting, while skeptics question whether uptake is accelerating enough to support growth and a path to profitability.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

UCO is drawing attention as traders react to volatile crude prices amid U.S.-Iran tensions and uncertainty over Strait of Hormuz shipping and oil supply. Supply-disruption fears support bullish oil positions, while hopes for diplomacy and increased supplies fuel bearish views; traders also question how closely the leveraged fund tracks oil moves.

Zoracles

A sharp, volume-driven rebound has renewed attention on ZORA, with traders debating whether it signals a sustained recovery or another short-lived pump after repeated reversals. Some also discuss Zoras move into Solana-based attention markets, while questioning whether that expansion creates direct value for token holders.

Sunrun, Inc. engages in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems. It sells solar service offerings and installs solar energy systems for homeowners. Customers can access its products through three channels: direct-to-consumer, solar partnerships, and strategic partnerships. The company was founded by Edward Harris Fenster, Robert Nat Kreamer, and Lynn Michelle Jurich in January 2007 and is headquartered in San Francisco, CA.

Sunrun Inc

Sunruns distributed AI-computing pilot, which would use customers solar-and-battery-equipped homes to host computing nodes, is driving attention and enthusiasm about a new data-center power opportunity. Traders are debating whether the concept can generate meaningful revenue, since the rollout is early and its economics remain unclear.

Verizon Communications, Inc. is a holding company, which engages in the provision of communications, information, and entertainment products and services. It operates through the following business segments: Consumer and Business. The Consumer segment provides consumer-focused wireless and wire line communications services and products. The Business segment offers wireless and wireline communications services and products, including FWA broadband, data, video and conferencing services, corporate networking solutions, security and managed network services, local and long-distance voice services, and network access to deliver various IoT services and products. The company was founded in 1983 and is headquartered in New York, NY.

Verizon Communications Inc

Verizon Communications Inc.

SpaceXs planned acquisition of low-band spectrum for Starlink Mobile has raised fears that it could eventually compete with Verizon and other U.S. wireless carriers, weighing heavily on telecom shares. Traders are divided between viewing the move as a long-term threat and calling the selloff an overreaction given the years of investment and infrastructure needed to build a competing network; some see Verizons dividend and cash flows as support.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

Exchange-delisting concerns are fueling bearish discussion, with traders debating the significance of Upbit and other platform changes; some holders argue the changes are limited or being mischaracterized. Bulls counter with JasmyChain activity and ecosystem partnerships as signs of development, while acknowledging that real adoption and token demand remain unproven.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

After Plunging 24% in 4 Weeks, Here's Why the Trend Might Reverse for Oculis Holding AG (OCS)

Oculis Holding AG (OCS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength?

Halozyme Therapeutics (HALO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Wall Street Analysts Believe Oculis Holding AG (OCS) Could Rally 199.75%: Here's is How to Trade

The mean of analysts' price targets for Oculis Holding AG (OCS) points to a 199.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Oculis Holding AG (OCS) Have the Potential to Rally 187.83% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 187.8% in Oculis Holding AG (OCS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Oculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue Estimates

Oculis Holding AG (OCS) delivered earnings and revenue surprises of +58.33% and +49.05%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Vertex Pharmaceuticals (VRTX) Q2 Earnings Lag Estimates

Vertex (VRTX) delivered earnings and revenue surprises of -1.25% and +3.32%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS PR Newswire NEW YORK, June 25, 2026 NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS PR Newswire NEW YORK, June 18, 2026 NEW YORK, June 18, 2026 /PRNewswire/ -- PomerantzLLP...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS PR Newswire NEW YORK, June 11, 2026 NEW YORK, June 11, 2026 /PRNewswire/ -- Pomerantz LLP...

Oculis Holding AG (OCS) Securities Fraud Investigation - Levi & Korsinsky

Oculis Holding AG (OCS) Securities Fraud Investigation - Levi & Korsinsky Oculis Holding AG (OCS) Securities Fraud Investigation - Levi & Korsinsky PR Newswire NEW YORK, June 8, 2026 Oculis Holding AG shares collapsed approximately 23% after Phase 3 DIAMOND trials for lead product OCS-01 failed to...

Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The firm's pipeline includes multiple product candidates in development such as, OCS-01, a topical retinal candidate for diabetic macular edema, OCS-02, a topical biologic candidate for dry eye disease, and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company was founded in 2016 and is headquartered in Zug, Switzerland.

Oculis Holding AG

OCS Stock Drops Over 23% — Eye Drop Trial For Diabetic Vision Loss Misses Target

Equity

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.48	--	--	N/A
Q2 '26	-$0.48	-$0.19	59.81%	BEAT
Q1 '26	-$0.51	-$0.60	-17.87%	MISSED
Q4 '25	-$0.50	-$0.54	-8.33%	MISSED
Q3 '25	-$0.51	-$0.41	19.73%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

OCS Earnings

Upcoming Earnings: Q3 '26

Historical Earnings